NEW ORLEANS (March 16, 2023) — Today, AxoSim celebrated the expansion of their footprint with the New Orleans BioInnovation Center (NOBIC) at a ribbon cutting at 1441 Canal Street. The event, followed by a reception in the NOBIC lobby, was attended by BioDistrict supporters including elected officials, business organizations and board members from both entities. 

The new partnership expands AxoSim’s current operation to more than 4,000 square feet at the NOBIC facility in the heart of the downtown BioDistrict. The additional lab space will allow AxoSim to grow its neuroscience drug discovery operations and accelerate their mission of empowering advancements in human neuroscience. The company’s proprietary NerveSim® and BrainSim® platforms provide accurate, predictive models of the human nervous system, rapidly delivering clinically actionable human data early in the drug development process. AxoSim’s platforms have the potential to reduce the time and cost of new drug R&D for neurodegenerative disorders, in addition to its applications in toxicology. The technology has been shown to achieve research milestones at a fraction of the time and cost of conventional animal testing, allowing AxoSim’s biopharma partners to develop more effective and safer drugs with greater speed and efficiency.

“I feel more driven by our mission than ever,” says AxoSim CEO Lowry Curley, PhD.  “Every client and partner we work with in our lab look to AxoSim for solutions to support better neuroscience drug discovery. Better preclinical data leads to more effective and safer drugs and ultimately better patient outcomes. For those patients suffering from neurodegenerative diseases like neuropathy, pain, ALS, MS, or Alzheimer’s, a new more effective drug is the best hope for a better quality of life.”

This opening exemplifies continued progress in development of New Orleans as a biotech hub by NOBIC and its affiliated companies and stakeholders.

“We are excited for Dr. Curley and the AxoSim team achieving this major milestone,” says NOBIC Executive Director Kris Khalil. “When our most promising startups raise private capital and grow locally, it moves our community one step closer to building a sustainable life science entrepreneurship ecosystem. In turn, this creates more high-paying specialized jobs in the region, keeping our brightest students and recruiting the best biotech and business talent to New Orleans.”

NOBIC is dedicated to growing the high-tech entrepreneurial system across the state, starting here in New Orleans. The center includes lab space for startups and established companies, like AxoSim, to conduct their research in the heart of downtown. The New Orleans BioFund program also offers various capital options to small businesses that may not qualify for traditional financing options, better positioning them for growth and success.

For more information on AxoSim and their innovative research please visit

For more information on NOBIC, please visit


About AxoSim: AxoSim empowers advancements in human neuroscience by partnering with biopharma companies to facilitate breakthroughs in devastating neurological diseases and disorders. Their proprietary drug discovery platforms NerveSim® and BrainSim® deliver clinically-relevant data to select better lead candidates with phenotypically accurate assays. AxoSim’s platforms have applications in peripheral neuropathy and neuropathic pain, disease modeling (such as ALS, MS, and CMT), and neurotoxicology. For more information, visit

About New Orleans BioInnovation Center: The New Orleans BioInnovation Center (“NOBIC”) is a nonprofit business incubator focused on advancing life science entrepreneurship and technology commercialization in Louisiana. The mission of NOBIC is to create a successful biotech ecosystem by providing emerging companies with customized commercialization services, premier facilities and a comprehensive support network. Through relationships with research institutions, economic development organizations and industry stakeholders, NOBIC helps its clients de-risk novel technologies, attract funding and improve global health outcomes. For more information, visit